Aarkstore Enterprise - Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts
Aarkstore announce a new report "Idiopathic Pulmonary Fibrosis - Pipeline Assessment
and Market Forecasts to 2017 " through its vast collection of market research report.
Summary
Pharmaceutical and healthcare report, "Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017" is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. The report identifies the key trends shaping and driving the global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global idiopathic pulmonary fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
The global Idiopathic Pulmonary Fibrosis (IPF) market was valued at $88m in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 23% from $88m in 2009 to $462m by 2017. Earlier, the IPF market was underserved due to a lack of approved products. In October 2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under regulatory review for approval in the US and EU. The expected increase in sales is due to the expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the anticipated approval of Letiaris and Tracleer. Gilead's Letiaris and Actelion's Tracleer are the most anticipated molecules in the IPF market.
Scope
The report provides information on the key driver and challenges of the idiopathic pulmonary fibrosis market. Its scope includes:
- Annualized global idiopathic pulmonary fibrosis market revenues data from 2001 to 2009, forecast forward for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include enzyme inhibitors, protein inhibitors, endothelin A antagonists, combination therapy, TNF alpha antagonists, platelet aggregation inhibitors, interferon alpha, interleukin inhibitors, immunosuppresants, growth hormone inhibitors, gene therapy, LPA1 receptor antagonists, tumor growth factor inhibitors and NK-1 antagonists.
- Analysis of the current and future market competition in the global idiopathic pulmonary fibrosis market. Key market players covered are Gilead Sciences, Actelion Ltd., Amgen Inc., InterMune Inc. and Amarillo Biosciences.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with idiopathic pulmonary fibrosis therapeutics.
Reasons to buy
The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global idiopathic pulmonary fibrosis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global idiopathic pulmonary fibrosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global idiopathic pulmonary fibrosis market landscape? Identify, understand and capitalize.
For more information, please visit:
http://www.aarkstore.com/reports/Idiopathic-Pulmonary-Fibrosis-Pipeline-Assessment-and-Market-Forecasts-to-2017-65417.htmlOr email us at press@aarkstore.com or call +919272852585
Aarkstore Enterprise - Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts
By: Pushpanjali
Email Marketing with Awber.com – The Lazy Benefits that Secured My Profit How To Flagstone Patio Scam Make a Profit With Social Media Aarkstore Enterprise - Acne - Pipeline Assessment and Market Forecasts to 2017 Aarkstore enterprise---North America In-Dash Navigation Systems Market 2009-2013 Aarkstore enterprise---North America Managed Security Services Market 2009-2013 Does MonaVie Really Work? The Truth Behind The MonaVie Drug Scam Aarkstore enterprise---Global 3D CAD Market 2009-2013 - Survey Based Report Key Trends and Developments in the Fragrances market in India The Conspiracy Of The Gurus in Affiliate Marketing Herbal Hair Solution Scam Aarkstore Enterprise - Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017 Let's Dance Louis Scam
Aarkstore Enterprise - Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts Anaheim